Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

• Main Authors: Saori Fukui (Author), Mitsuru Seki (Author), Takaomi Minami (Author), Kazuhiko Kotani (Author), Kensuke Oka (Author), Akiko Yokomizo (Author), Daisuke Matsubara (Author), Tomoyuki Sato (Author), Yasuyuki Nozaki (Author), Mari Saito (Author), Yutaka Kikuchi (Author), Kenji Miyamoto (Author), Yukifumi Monden (Author), Takanori Yamagata (Author)
• Format: Book
• Published: BMC, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background High-dose intravenous immunoglobulin (IVIG) is the mainstay of treatment for Kawasaki disease (KD). Usually, 2 g/kg of IVIG is administered over 10-24 h, depending on the institution or physician, but the association between infusion speed and effectiveness has not been reported....